Pharmasset

Gilead Bets on Hepatitis C Data to Back Pharmasset Deal

Gilead Bets on Hepatitis C Data to Back Pharmasset Deal

Bloomberg

Hepatitis C Remains A Hot Play

Hepatitis C Remains A Hot Play

Seeking Alpha

Friday's Overreaction Provides Great Entry Point For Gilead

Friday's Overreaction Provides Great Entry Point For Gilead

Seeking Alpha

Analyzing 5 Biotech Stocks And Their Takeover Potential

Analyzing 5 Biotech Stocks And Their Takeover Potential

Seeking Alpha

Gilead nears completion of Pharmasset deal

Gilead nears completion of Pharmasset deal

Yahoo/AP

3 Reasons Hep C Premiums Might Not Last

3 Reasons Hep C Premiums Might Not Last

Motley Fool

A White Hot Hep C Market: What The Wags Say

A White Hot Hep C Market: What The Wags Say

Pharmalot

Shares of hepatitis C drug developers rise on Bristol-Myers' $2.5B deal for Inhibitex

Shares of hepatitis C drug developers rise on Bristol-Myers' $2.5B deal for Inhibitex

Yahoo/AP

Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period

Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period

Yahoo/BusinessWire

Pharmasset: M&A Presents Interesting Options Plays

Pharmasset: M&A Presents Interesting Options Plays

Seeking Alpha